Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027.
German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.
Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.
Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.
Researchers from Mabqi SAS presented the preclinical profile of MQI-181, an antibody-drug conjugate (ADC) composed of a human anti-CD30 antibody (18D03) linked to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable MC-VC-PAB linker, with a drug-antibody ratio of 4.
Canwell Pharma Inc. has obtained IND approval from the FDA for CAN-016, a novel antibody-drug conjugate (ADC). The company will initiate a phase I study in patients with HER2-expressing solid tumors who have experienced disease progression following prior ADC therapies.
Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.
Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform.
Biocad Ltd. has disclosed new antibody-drug conjugates consisting of antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.
RSS
